CureVac Revenue Per Share vs Capex To Revenue Analysis

CVAC Stock

USD 2.66 0.10 3.91%

CureVac NV financial indicator trend analysis is way more than just evaluating CureVac NV prevailing accounting drivers to predict future trends. We encourage investors to analyze account correlations over time for multiple indicators to determine whether CureVac NV is a good investment. Please check the relationship between CureVac NV Revenue Per Share and its Capex To Revenue accounts. Check out Trending Equities to better understand how to build diversified portfolios, which includes a position in CureVac NV. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in nation.

For information on how to trade CureVac Stock refer to our How to Trade CureVac Stock guide.

Revenue Per Share vs Capex To Revenue

Revenue Per Share vs Capex To Revenue Correlation Analysis

The overlapping area represents the amount of trend that can be explained by analyzing historical patterns of CureVac NV Revenue Per Share account and Capex To Revenue. At this time, the significance of the direction appears to have almost no relationship.

The correlation between CureVac NV's Revenue Per Share and Capex To Revenue is 0.16. Overlapping area represents the amount of variation of Revenue Per Share that can explain the historical movement of Capex To Revenue in the same time period over historical financial statements of CureVac NV, assuming nothing else is changed. The correlation between historical values of CureVac NV's Revenue Per Share and Capex To Revenue is a relative statistical measure of the degree to which these accounts tend to move together. The correlation coefficient measures the extent to which Revenue Per Share of CureVac NV are associated (or correlated) with its Capex To Revenue. Values of the correlation coefficient range from -1 to +1, where. The correlation of zero (0) is possible when Capex To Revenue has no effect on the direction of Revenue Per Share i.e., CureVac NV's Revenue Per Share and Capex To Revenue go up and down completely randomly.

Correlation Coefficient

0.16

Relationship Direction	Positive
Relationship Strength	Insignificant

View All Relationships

Revenue Per Share

The amount of revenue generated by a company per share of stock, calculated by dividing total revenue by the average number of shares outstanding.

Capex To Revenue

The ratio of a company's capital expenditures to its total revenue, indicating how much of the revenue is used for acquiring or maintaining physical assets.

Most indicators from CureVac NV's fundamental ratios are interrelated and interconnected. However, analyzing fundamental ratios indicators one by one will only give a small insight into CureVac NV current financial condition. On the other hand, looking into the entire matrix of fundamental ratios indicators, and analyzing their relationships over time can provide a more complete picture of the company financial strength now and in the future. Check out Trending Equities to better understand how to build diversified portfolios, which includes a position in CureVac NV. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in nation.

For information on how to trade CureVac Stock refer to our How to Trade CureVac Stock guide.At present, CureVac NV's Sales General And Administrative To Revenue is projected to slightly decrease based on the last few years of reporting.

	2021	2022	2023	2024 (projected)
Depreciation And Amortization	35.9M	26.2M	23.4M	20.3M
Interest Income	10.1M	4.0M	12.9M	13.6M

Depreciation And Amortization Interest Income

CureVac NV fundamental ratios Correlations

	Total Assets	Other Current Liab	Total Current Liabilities	Total Stockholder Equity	Other Liab	Net Tangible Assets	Property Plant And Equipment Net	Current Deferred Revenue	Net Debt	Retained Earnings	Accounts Payable	Cash	Non Current Assets Total	Non Currrent Assets Other	Other Assets	Cash And Short Term Investments	Net Receivables	Common Stock Total Equity	Common Stock Shares Outstanding	Short Term Investments	Non Current Liabilities Total	Inventory	Other Current Assets	Other Stockholder Equity	Total Liab	Deferred Long Term Liab
Total Assets		0.77	0.94	0.98	0.75	0.97	0.72	0.92	-0.97	-0.67	0.69	0.98	0.72	-0.24	-0.34	0.98	0.43	0.91	-0.1	-0.8	0.76	0.77	0.9	0.39	0.96	-0.32
Other Current Liab	0.77		0.94	0.83	0.24	0.84	0.75	0.52	-0.68	-0.69	0.93	0.69	0.74	-0.31	-0.42	0.69	0.88	0.78	0.3	-0.67	0.23	0.98	0.43	0.21	0.64	-0.51
Total Current Liabilities	0.94	0.94		0.96	0.52	0.95	0.77	0.76	-0.88	-0.71	0.87	0.89	0.76	-0.26	-0.38	0.89	0.7	0.89	0.09	-0.77	0.53	0.93	0.71	0.29	0.85	-0.43
Total Stockholder Equity	0.98	0.83	0.96		0.62	1.0	0.82	0.84	-0.92	-0.77	0.78	0.93	0.82	-0.31	-0.45	0.93	0.49	0.95	0.05	-0.79	0.63	0.83	0.82	0.38	0.9	-0.47
Other Liab	0.75	0.24	0.52	0.62		0.61	0.18	0.95	-0.84	-0.2	0.06	0.84	0.19	-0.09	0.03	0.85	-0.12	0.53	-0.56	-0.49	0.96	0.18	0.93	0.49	0.87	0.21
Net Tangible Assets	0.97	0.84	0.95	1.0	0.61		0.84	0.83	-0.91	-0.77	0.77	0.92	0.84	-0.33	-0.47	0.91	0.49	0.95	0.08	-0.79	0.61	0.83	0.8	0.4	0.88	-0.48
Property Plant And Equipment Net	0.72	0.75	0.77	0.82	0.18	0.84		0.45	-0.55	-0.96	0.79	0.59	1.0	-0.55	-0.78	0.57	0.52	0.9	0.58	-0.8	0.21	0.8	0.43	0.4	0.54	-0.8
Current Deferred Revenue	0.92	0.52	0.76	0.84	0.95	0.83	0.45		-0.96	-0.43	0.36	0.97	0.46	-0.16	-0.13	0.97	0.14	0.74	-0.38	-0.67	0.93	0.48	0.97	0.47	0.98	-0.01
Net Debt	-0.97	-0.68	-0.88	-0.92	-0.84	-0.91	-0.55	-0.96		0.48	-0.56	-0.99	-0.55	0.07	0.12	-0.99	-0.32	-0.78	0.33	0.68	-0.85	-0.65	-0.94	-0.3	-0.98	0.1
Retained Earnings	-0.67	-0.69	-0.71	-0.77	-0.2	-0.77	-0.96	-0.43	0.48		-0.72	-0.54	-0.96	0.71	0.9	-0.53	-0.47	-0.92	-0.64	0.79	-0.18	-0.74	-0.41	-0.57	-0.51	0.86
Accounts Payable	0.69	0.93	0.87	0.78	0.06	0.77	0.79	0.36	-0.56	-0.72		0.58	0.78	-0.18	-0.45	0.57	0.85	0.75	0.37	-0.63	0.1	0.98	0.34	0.0	0.52	-0.65
Cash	0.98	0.69	0.89	0.93	0.84	0.92	0.59	0.97	-0.99	-0.54	0.58		0.59	-0.15	-0.2	1.0	0.35	0.83	-0.26	-0.74	0.85	0.68	0.95	0.37	0.99	-0.16
Non Current Assets Total	0.72	0.74	0.76	0.82	0.19	0.84	1.0	0.46	-0.55	-0.96	0.78	0.59		-0.54	-0.78	0.57	0.5	0.91	0.57	-0.79	0.22	0.79	0.45	0.4	0.54	-0.8
Non Currrent Assets Other	-0.24	-0.31	-0.26	-0.31	-0.09	-0.33	-0.55	-0.16	0.07	0.71	-0.18	-0.15	-0.54		0.89	-0.14	-0.14	-0.55	-0.68	0.38	0.08	-0.25	-0.06	-0.89	-0.13	0.67
Other Assets	-0.34	-0.42	-0.38	-0.45	0.03	-0.47	-0.78	-0.13	0.12	0.9	-0.45	-0.2	-0.78	0.89		-0.19	-0.26	-0.7	-0.8	0.53	0.11	-0.45	-0.1	-0.67	-0.17	0.91
Cash And Short Term Investments	0.98	0.69	0.89	0.93	0.85	0.91	0.57	0.97	-0.99	-0.53	0.57	1.0	0.57	-0.14	-0.19		0.34	0.82	-0.28	-0.72	0.85	0.66	0.95	0.37	0.99	-0.15
Net Receivables	0.43	0.88	0.7	0.49	-0.12	0.49	0.52	0.14	-0.32	-0.47	0.85	0.35	0.5	-0.14	-0.26	0.34		0.47	0.4	-0.51	-0.1	0.88	0.04	-0.06	0.31	-0.39
Common Stock Total Equity	0.91	0.78	0.89	0.95	0.53	0.95	0.9	0.74	-0.78	-0.92	0.75	0.83	0.91	-0.55	-0.7	0.82	0.47		0.29	-0.85	0.51	0.8	0.72	0.56	0.8	-0.66
Common Stock Shares Outstanding	-0.1	0.3	0.09	0.05	-0.56	0.08	0.58	-0.38	0.33	-0.64	0.37	-0.26	0.57	-0.68	-0.8	-0.28	0.4	0.29		-0.27	-0.59	0.34	-0.44	0.3	-0.3	-0.79
Short Term Investments	-0.8	-0.67	-0.77	-0.79	-0.49	-0.79	-0.8	-0.67	0.68	0.79	-0.63	-0.74	-0.79	0.38	0.53	-0.72	-0.51	-0.85	-0.27		-0.56	-0.72	-0.63	-0.44	-0.77	0.4
Non Current Liabilities Total	0.76	0.23	0.53	0.63	0.96	0.61	0.21	0.93	-0.85	-0.18	0.1	0.85	0.22	0.08	0.11	0.85	-0.1	0.51	-0.59	-0.56		0.21	0.94	0.32	0.89	0.27
Inventory	0.77	0.98	0.93	0.83	0.18	0.83	0.8	0.48	-0.65	-0.74	0.98	0.68	0.79	-0.25	-0.45	0.66	0.88	0.8	0.34	-0.72	0.21		0.42	0.12	0.63	-0.58
Other Current Assets	0.9	0.43	0.71	0.82	0.93	0.8	0.43	0.97	-0.94	-0.41	0.34	0.95	0.45	-0.06	-0.1	0.95	0.04	0.72	-0.44	-0.63	0.94	0.42		0.37	0.95	-0.02
Other Stockholder Equity	0.39	0.21	0.29	0.38	0.49	0.4	0.4	0.47	-0.3	-0.57	0.0	0.37	0.4	-0.89	-0.67	0.37	-0.06	0.56	0.3	-0.44	0.32	0.12	0.37		0.39	-0.36
Total Liab	0.96	0.64	0.85	0.9	0.87	0.88	0.54	0.98	-0.98	-0.51	0.52	0.99	0.54	-0.13	-0.17	0.99	0.31	0.8	-0.3	-0.77	0.89	0.63	0.95	0.39		-0.09
Deferred Long Term Liab	-0.32	-0.51	-0.43	-0.47	0.21	-0.48	-0.8	-0.01	0.1	0.86	-0.65	-0.16	-0.8	0.67	0.91	-0.15	-0.39	-0.66	-0.79	0.4	0.27	-0.58	-0.02	-0.36	-0.09

Click cells to compare fundamentals

CureVac NV Account Relationship Matchups

CureVac NV fundamental ratios Accounts

	2019	2020	2021	2022	2023	2024 (projected)
Total Assets	130.6M	1.5B	1.2B	860.5M	788.2M	838.7M
Other Current Liab	13.3M	56.1M	171.4M	44.7M	88.0M	70.9M
Total Current Liabilities	28.1M	247.6M	357.7M	156.2M	186.4M	184.1M
Total Stockholder Equity	(42.8M)	711.3M	688.5M	533.3M	516.9M	447.2M
Net Tangible Assets	(48.2M)	697.9M	676.2M	501.5M	576.7M	407.8M
Property Plant And Equipment Net	66.8M	104.8M	200.4M	241.7M	278.6M	171.9M
Current Deferred Revenue	7.5M	158.0M	55.8M	36.8M	46.3M	56.8M
Net Debt	48.5M	(1.3B)	(782.6M)	(453.7M)	(360.6M)	(378.7M)
Retained Earnings	(515.9M)	(645.1M)	(1.1B)	(1.3B)	(1.6B)	(1.5B)
Accounts Payable	5.3M	17.6M	122.3M	68.2M	46.4M	49.3M
Cash	30.7M	1.3B	811.5M	495.8M	402.8M	565.5M
Non Current Assets Total	73.4M	121.5M	218.2M	276.4M	309.9M	192.9M
Non Currrent Assets Other	967K	1.1M	1.2M	1.7M	(13.0M)	(12.4M)
Other Assets	6.3M	7.5M	5.6M	3.0M	1.0	0.95
Cash And Short Term Investments	32.1M	1.3B	816.1M	500.3M	402.8M	575.1M
Net Receivables	17.7M	1.8M	53.7M	9.0M	17.1M	19.5M
Common Stock Shares Outstanding	186.9M	132.2M	186.0M	189.1M	220.8M	200.0M
Short Term Investments	1.5M	2.6M	4.6M	4.5M	2.7M	2.5M
Liabilities And Stockholders Equity	130.6M	1.5B	1.2B	860.5M	788.2M	838.7M
Non Current Liabilities Total	145.3M	552.4M	112.0M	171.0M	84.9M	150.8M
Capital Lease Obligations	14.1M	55.3M	28.9M	42.1M	41.8M	33.4M
Inventory	6.2M	14.5M	56.2M	24.0M	24.8M	23.6M
Other Current Assets	1.2M	48.3M	14.0M	20.3M	9.0M	17.5M
Other Stockholder Equity	493.4M	1.4B	(5.8M)	(1.5M)	2.1B	2.2B
Total Liab	173.4M	800.0M	469.8M	327.2M	271.3M	391.5M
Deferred Long Term Liab	966K	1.0M	515K	302K	271.8K	258.2K
Net Invested Capital	22.2M	711.3M	688.5M	533.3M	516.9M	459.1M
Property Plant And Equipment Gross	61.7M	104.8M	247.4M	258.7M	301.8M	186.0M
Total Current Assets	57.2M	1.4B	940.0M	584.0M	478.4M	645.8M
Accumulated Other Comprehensive Income	472.4M	1.3B	1.7B	1.8B	2.1B	1.4B
Non Current Liabilities Other	529K	284K	264K	19K	17.1K	16.2K
Net Working Capital	29.1M	1.1B	582.3M	427.8M	292.0M	461.7M
Short Term Debt	2.0M	3.2M	3.5M	5.0M	5.0M	3.5M
Intangible Assets	5.7M	14.1M	13.2M	19.3M	15.9M	13.7M

Also Currently Popular

Analyzing currently trending equities could be an opportunity to develop a better portfolio based on different market momentums that they can trigger. Utilizing the top trending stocks is also useful when creating a market-neutral strategy or pair trading technique involving a short or a long position in a currently trending equity.

RSI	Rush Street Interactive
OKTA	Okta Inc
BAC	Bank of America

When determining whether CureVac NV offers a strong return on investment in its stock, a comprehensive analysis is essential. The process typically begins with a thorough review of CureVac NV's financial statements, including income statements, balance sheets, and cash flow statements, to assess its financial health. Key financial ratios are used to gauge profitability, efficiency, and growth potential of Curevac Nv Stock. Outlined below are crucial reports that will aid in making a well-informed decision on Curevac Nv Stock:

How To Invest In CureVac

Details

Is CureVac Stock a good investment?

Details

What is CureVac NV's Net Worth?

Details

Largest Biotechnology Companies

View

Largest Pharmaceuticals, Biotechnology & Life Sciences Companies

View

Check out Trending Equities to better understand how to build diversified portfolios, which includes a position in CureVac NV. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in nation.

For information on how to trade CureVac Stock refer to our How to Trade CureVac Stock guide.

You can also try the Portfolio Suggestion module to get suggestions outside of your existing asset allocation including your own model portfolios.

Is Biotechnology space expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of CureVac NV. If investors know CureVac will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about CureVac NV listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.

Earnings Share

0.5

Revenue Per Share

0.294

Quarterly Revenue Growth

0.905

Return On Assets

(0.25)

Return On Equity

(0.54)

The market value of CureVac NV is measured differently than its book value, which is the value of CureVac that is recorded on the company's balance sheet. Investors also form their own opinion of CureVac NV's value that differs from its market value or its book value, called intrinsic value, which is CureVac NV's true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because CureVac NV's market value can be influenced by many factors that don't directly affect CureVac NV's underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.

Please note, there is a significant difference between CureVac NV's value and its price as these two are different measures arrived at by different means. Investors typically determine if CureVac NV is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, CureVac NV's price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.

Macroaxis helps investors of all levels and skills to maximize the upside of all their holdings and minimize the risk associated with market volatility, economic swings, and company-specific events. View terms and conditions

Feedback Blog

Made with optimal in San Francisco

2024 Macroaxis LLC

CureVac Revenue Per Share vs Capex To Revenue Analysis

Revenue Per Share vs Capex To Revenue

Revenue Per Share vs Capex To Revenue Correlation Analysis

Correlation Coefficient

Revenue Per Share

Capex To Revenue

CureVac NV fundamental ratios Correlations

CureVac NV Account Relationship Matchups

High Positive Relationship

High Negative Relationship

CureVac NV fundamental ratios Accounts

Also Currently Popular

COMMON DESTINATIONS

MAIN CATEGORIES

COMPANY

Net Tangible Assets	+ 1.0	Total Stockholder Equity
Non Current Assets Total	+ 1.0	Property Plant And Equipment Net
Cash And Short Term Investments	+ 1.0	Cash
Total Liab	+ 0.99	Cash
Total Liab	+ 0.99	Cash And Short Term Investments
Total Stockholder Equity	+ 0.98	Total Assets

Cash And Short Term Investments	- 0.99	Net Debt
Cash	- 0.99	Net Debt
Total Liab	- 0.98	Net Debt
Net Debt	- 0.97	Total Assets
Non Current Assets Total	- 0.96	Retained Earnings
Net Debt	- 0.96	Current Deferred Revenue